Articles Tagged With: metformin
-
Metformin Use Is Associated with Decreased Diabetes-Associated Dementia
In two recent cohort studies, metformin use was found to decrease the risk of developing dementia in older adults with type 2 diabetes mellitus.
-
Metformin Use Is Associated with Decreased Diabetes-Associated Dementia
In two recent cohort studies, metformin use was found to decrease the risk of developing dementia in older adults with type 2 diabetes mellitus.
-
Who Benefits Most from Tirzepatide Among Patients with Type 2 Diabetes?
Females, patients of white or Asian race, younger patients, and those taking metformin benefit the most from treatment with tirzepatide.
-
Metformin for the Management of Early Gestational Diabetes
The administration of metformin in the early stages of gestational diabetes did not demonstrate superiority over placebo in relation to the need to start insulin therapy prior to delivery, or on fasting blood glucose concentrations ≥ 5.1 mmol/L at either the 32nd or 38th weeks of gestation (composite primary outcome).
-
Is Metformin a Wonder Drug?
An analysis of patients taking metformin for diabetes showed they were less likely to report back, knee, neck/shoulder, or multisite musculoskeletal pain.
-
Prior Metformin Use in Patients with Diabetes Hospitalized for COVID-19
Investigators found metformin use before COVID-19 hospitalization for patients with diabetes was associated with a lower risk of death.
-
What Are the Roles of the Combined Oral Contraceptive Pill and Metformin in the Management of Polycystic Ovary Syndrome?
This systematic review documents the effectiveness of combined oral contraceptive pills in treating hyperandrogenism and irregular menses, and of metformin in addressing the metabolic disturbances in women with polycystic ovary syndrome.
-
Pharmacologic Management of Type 2 Diabetes Mellitus: Part 2
This two-part series of articles will address pharmacological agents, except insulin, used to manage type 2 diabetes mellitus. Part 1 covered sodium glucose co-transporter-2 inhibitors, incretin-based therapies, amylin analog, and dopamine receptor agonists. Part 2 will focus on biguanides, thiazolidinediones, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and bile acid resins, as well as the authors’ treatment recommendations. Appendix A (http://bit.ly/2eyB4Px) is a comprehensive table of the effectiveness and costs of various combination therapies.